Docstoc
EXCLUSIVE OFFER FOR DOCSTOC USERS
Try the all-new QuickBooks Online for FREE.  No credit card required.

ISTA Pharmaceuticals Inc Product Pipeline Review

Document Sample
ISTA Pharmaceuticals Inc Product Pipeline Review Powered By Docstoc
					ISTA Pharmaceuticals, Inc. – Product Pipeline
Review – H2 2011




                                     Phone:    +44 20 8123 2220
                                     Fax:      +44 207 900 3970
                                     office@marketpublishers.com

                                     http://marketpublishers.com
                                                                                      Phone: +44 20 8123 2220
                                                                                      http://marketpublishers.com



ISTA Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011
Global Markets Direct

Date: Nov, 2011
Pages: 107
Price: US$ 500.00
ID: IB4BA146351EN

ISTA Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “ISTA Pharmaceuticals, Inc. - Product Pipeline Review -
H2 2011” provides data on the ISTA Pharmaceuticals, Inc.’s research and development focus. The report
includes information on current developmental pipeline, complete with latest updates, and features on
discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases,
ISTA Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press
releases, both from ISTA Pharmaceuticals, Inc. and industry-specific third party sources, put together by
Global Markets Direct’s team.

Scope


           ISTA Pharmaceuticals, Inc. - Brief ISTA Pharmaceuticals, Inc. overview including business
           description, key information and facts, and its locations and subsidiaries.
           Review of current pipeline of ISTA Pharmaceuticals, Inc. human therapeutic division.
           Overview of pipeline therapeutics across various therapy areas.
           Coverage of current pipeline molecules in various stages of drug development, including the
           combination treatment modalities, across the globe.
           Product profiles for late stage and clinical stage products of ISTA Pharmaceuticals, Inc. with
           complete description of the product’s developmental history, mechanism of action, therapeutic
           class, target and major milestones.
           Recent updates of the ISTA Pharmaceuticals, Inc.’s pipeline in the last quarter.
           Key discontinued and dormant projects.
           Latest news and deals relating to the products.

Reasons to buy


           Evaluate ISTA Pharmaceuticals, Inc.’s strategic position with total access to detailed information on
           its product pipeline.
           Assess the growth potential of ISTA Pharmaceuticals, Inc. in its therapy areas of focus.
           Identify new drug targets and therapeutic classes in the ISTA Pharmaceuticals, Inc.’s R&D portfolio
           and develop key strategic initiatives to reinforce pipeline in those areas.
           Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
           Exploit collaboration and partnership opportunities with ISTA Pharmaceuticals, Inc..
           Avoid Intellectual Property Rights related issues.
           Explore the dormant and discontinued projects of ISTA Pharmaceuticals, Inc. and identify potential
           opportunities in those areas.




ISTA Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011                                                      2
                                                                 Phone: +44 20 8123 2220
                                                                 http://marketpublishers.com



Table of Content
ISTA Pharmaceuticals, Inc. Snapshot
ISTA Pharmaceuticals, Inc. Overview
Key Information
Key Facts
ISTA Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
ISTA Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
ISTA Pharmaceuticals, Inc. – Pipeline Products Glance
ISTA Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
ISTA Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
ISTA Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
ISTA Pharmaceuticals, Inc. – Drug Profiles
Bepotastine Nasal Combination
  Product Description
  Mechanism of Action
  R&D Progress
Bepotastine Nasal Spray
  Product Description
  Mechanism of Action
  R&D Progress
Bromfenac Adjunct
  Product Description
  Mechanism of Action
  R&D Progress
Ecabet
  Product Description
  Mechanism of Action
  R&D Progress
Iganidipine
  Product Description
  Mechanism of Action
  R&D Progress
Latanoprost
  Product Description
  Mechanism of Action
  R&D Progress
Low-Concentration Bromday
  Product Description
  Mechanism of Action
  R&D Progress
Remura
  Product Description
  Mechanism of Action
  R&D Progress
Strong Steroids
  Product Description
  Mechanism of Action

ISTA Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011                                 3
                                                                                Phone: +44 20 8123 2220
                                                                                http://marketpublishers.com


  R&D Progress
T-Pred
  Product Description
  Mechanism of Action
  R&D Progress
ISTA Pharmaceuticals, Inc. – Pipeline Analysis
ISTA Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
ISTA Pharmaceuticals, Inc. - Pipeline Products By Target
ISTA Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
ISTA Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
ISTA Pharmaceuticals, Inc. – Recent Pipeline Updates
ISTA Pharmaceuticals, Inc. – Company Statement
ISTA Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
May 31, 2007: ISTA Pharmaceuticals Announces Positive Preliminary Results From Ecabet Sodium Phase
IIb Study
May 30, 2006: ISTA Pharmaceuticals Is Initiating Phase III Clinical Trials of a New Once-Daily Formulation
of Xibrom for the Treatment of Ocular Pain and Inflammation Following Cataract Surgery.
Jan 30, 2006: ISTA Pharmaceuticals Receives FDA Approval for Expanded Indication of Xibrom to Treat
Pain Following Cataract Surgery.
Jan 30, 2004: ISTA Pharmaceuticals Announces Vitrase Phase III Data Presented at Hawaiian Eye
Meeting
Jul 29, 2004: ISTA Pharmaceuticals Launches Istalol in the United States.
Oct 28, 2004: FDA Grants ISTA Pharmaceuticals' Vitrase Five-Year Market Exclusivity
Sep 28, 2004: ISTA Pharmaceuticals and Allergan Announce New Vitrase Agreement
Jul 28, 2011: ISTA Pharmaceuticals Reports Results From First of Two Trials In REMURA Phase III
Clinical Program For Dry Eye Disease
Jul 28, 2003: ISTA Pharmaceuticals Announces FDA Approvable Letter for ISTALOL
Apr 28, 2011: ISTA Pharmaceuticals Reports Positive Topline Results From Phase II Trial Of Bepotastine
Besilate Nasal Spray
Mar 28, 2005: ISTA Pharmaceuticals Receives FDA Approval for Xibrom for the Treatment of Ocular
Inflammation Following Cataract Surgery; - Xibrom will be ISTA's Third Product Launched in the U.S.
Market -
Jan 28, 2003: FDA Advisory Committee to Consider ISTA Pharmaceuticals' Vitrase on March 17, 2003
Sep 27, 2010: ISTA Announces Results From REMURA Phase II Study At International Conference On
Tear Film And Ocular Surface
Sep 27, 2002: ISTA Pharmaceuticals Announces Submission of New Drug Application For ISTALOL, a
Unique Formulation of Timolol
May 27, 2011: Mitsubishi Announces Launch Of Anti-Allergy Agent, Bepotastine Besilate In China And
Indonesia.
Oct 26, 2004: ISTA Pharmaceuticals' Istalol Receives 'BT' Rating From FDA, Disallowing Generic
Substitution at Pharmacies
Sep 26, 2007: ISTA Acquires Exclusive North American Rights To Bepotastine
Aug 26, 2009: ISTA says daily Xibrom eye drops met goal in study
Jul 26, 2004: FDA Accepts ISTA Pharmaceuticals' New Drug Application for Xibrom
Aug 25, 2009: STA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support
sNDA Filing for Once-Daily Xibrom 0.09%
May 25, 2004: ISTA Pharmaceuticals Announces Submission of Xibrom NDA to the FDA.
Jan 23, 2009: Announcement Of Positive Results For Phase IIb Study Of Ecabet Sodium.
Sep 22, 2003: ISTA Pharmaceuticals Presents Vitrase Phase III Data Analysis at Retina Society Annual
Meeting
Mar 22, 2011: ISTA Pharmaceuticals Highlights BEPREVE Clinical Data At 2011 American Academy of
Allergy, Asthma and Immunology Annual Meeting
Dec 21, 2007: ISTA Pharmaceuticals Submits New Drug Application for Xibrom QD (once-daily).
ISTA Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011                                                4
                                                                                 Phone: +44 20 8123 2220
                                                                                 http://marketpublishers.com


Dec 21, 2007: ISTA Pharmaceuticals Submits New Drug Application for Xibrom QD (once-daily).
Dec 21, 2007: ISTA Pharmaceuticals Submits New Drug Application for Xibrom QD (once-daily).
Sep 21, 2004: FDA Grants ISTA Pharmaceuticals' Vitrase Three-Year Market Exclusivity
Aug 21, 2003: ISTA Pharmaceuticals Presented Vitrase Phase III Data At American Society of Retina
Specialists Meeting
Mar 21, 2005: ISTA Pharmaceuticals Files IND For Phase IIb Trial Of Ecabet Sodium
Feb 21, 2006: ISTA Pharmaceuticals Announces Positive Preliminary Results From Phase IIb Trial Of
Ecabet Sodium For The Treatment Of Dry Eye Syndrome
Dec 20, 2001: ISTA Pharmaceuticals Announces Partnership With Otsuka Pharmaceutical Co., Ltd. for
Vitrase
Oct 20, 2005: ISTA Pharmaceuticals Announces Phase III Data Demonstrating that a Single Intravitreous
Injection of Vitrase Results in Improved Visual Acuity.
Aug 20, 2003: FDA Grants Priority Review for ISTA Pharmaceuticals' Vitrase NDA
Jun 19, 2006: ISTA Pharmaceuticals Expands Product Pipeline With Two Licensing Agreements For
Exclusive North American Rights To Investigational Glaucoma Treatments
Jun 19, 2006: ISTA Pharmaceuticals Expands Product Pipeline With Two Licensing Agreements For
Exclusive North American Rights To Investigational Glaucoma Treatments
Dec 18, 2003: ISTA Pharmaceuticals Announces Achievement of Phase III Patient Enrollment Goal for
Xibrom
Dec 17, 2009: ISTA Pharmaceuticals Submits New Drug Application Of XiDay For The Treatment Of
Ocular Inflammation With The FDA
Dec 17, 2002: ISTA Pharmaceuticals Announces FDA Acceptance of Vitrase NDA
Nov 17, 2010: ISTA Pharmaceuticals Granted Three-Year Market Exclusivity for BROMDAY
Nov 17, 2010: ISTA Pharmaceuticals Receives Three-Year Market Exclusivity For BROMDAY
Oct 17, 2005: STA Pharmaceuticals' Xibrom Receives Award for Best New Branded Pharmaceutical
Introduction in 2005.
Oct 16, 2010: ISTA Receives FDA Approval For BROMDAY
Sep 16, 2010: ISTA Pharmaceuticals Initiates Phase III Clinical Program For REMURA In Dry Eye Disease
Dec 14, 2010: ISTA Begins Phase II Study Of Bepotastine Besilate Nasal Spray In Allergic Rhinitis
Jul 14, 2010: ISTA Initiates Clinical Development Of Bepotastine Besilate Nasal Spray For Treatment Of
Symptoms Associated With Seasonal Allergic Rhinitis
Jul 14, 2010: Phase I/II Clinical Study Of Bepotastine Besilate Nasal Spray Initiated For Seasonal Allergic
Rhinitis
Oct 13, 2011: ISTA Pharmaceuticals Announces Statistically Significant Phase III Results For PROLENSA
Oct 13, 2011: ISTA Pharmaceuticals Reports Top-line Results From Second Of Two Studies In REMURA
Phase III Clinical Program For Dry Eye Disease
Apr 13, 2006: ISTA Pharmaceuticals Announces Xibrom and Vitrase Clinical Data to be Presented at the
2006 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Apr 13, 2006: ISTA Pharmaceuticals Announces Xibrom and Vitrase Clinical Data to be Presented at the
2006 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Apr 13, 2006: ISTA Pharmaceuticals Announces Xibrom and Vitrase Clinical Data to be Presented at the
2006 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
Nov 12, 2007: ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom QD
(Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
Dec 10, 2001: STA Pharmaceuticals Announces Date for Release of Phase III Clinical Trial Results of
Vitrase for the Treatment of Severe Vitreous Hemorrhage
Apr 10, 2002: ISTA Pharmaceuticals to Proceed With NDA Filing for Vitrase
Jun 09, 2003: ISTA Pharmaceuticals Presented Vitrase Phase III Data At European Society of
Ophthalmology Meeting
Mar 09, 2010: Ista Receives Action Date For FDA Review Of Once-Daily XiDay
Mar 09, 2004: ISTA Pharmaceuticals Announces Positive Results From Xibrom U.S. Phase III Trials;
Conference Call to be Held at 11 A.M. Eastern Standard Time.
Feb 08, 2011: ISTA To Stop Sales Of Twice-daily XIBROM
Feb 08, 2007: ISTA Pharmaceuticals Announces Positive Preliminary Xibrom Once-daily Formulation
Clinical Results From U.S. Phase III Trials.
ISTA Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011                                                 5
                                                                             Phone: +44 20 8123 2220
                                                                             http://marketpublishers.com


Oct 07, 2003: ISTA Pharmaceuticals Announces FDA Acceptance of Second Vitrase NDA
Sep 07, 2011: Pilot Study Suggests Bromfenac May Provide Added Efficacy Over Ranibizumab Alone For
Treatment Of Neovascular Age-Related Macular Degeneration
Sep 07, 2005: ISTA Pharmaceuticals Announces Publication of Vitrase Phase III Results in the American
Journal of Ophthalmology.
Jun 07, 2004: ISTA Pharmaceuticals Receives FDA Approval for Istalol for the Treatment of Glaucoma
Jan 07, 2003: ISTA Pharmaceuticals Announces FDA Acceptance of ISTALOL NDA
Jan 07, 2002: ISTA Pharmaceuticals Announces Clinical Trial Results of Vitrase For the Treatment of
Diabetic Retinopathy
Oct 06, 2010: ISTA Reports Positive Preliminary Results From Phase I/II Clinical Study Of Bepotastine
Besilate Nasal Spray In Seasonal Allergic Rhinitis
May 06, 2004: ISTA Pharmaceuticals Receives FDA Approval for Vitrase for Use as a Spreading Agent
Mar 06, 2002: ISTA Pharmaceuticals Proceeds with Analysis of Pivotal Phase III Vitrase Data
Feb 06, 2004: Review of ISTA Pharmaceuticals' New Drug Application for Vitrase for Use as a Spreading
Agent Extended 90 Days by FDA
Jan 06, 2005: ISTA Pharmaceuticals Launches Vitrase in the United States
Aug 05, 2003: ISTA Pharmaceuticals Announces Submission of Second Vitrase NDA to the FDA
Jul 05, 2001: ISTA Announces Completion of Enrollment in the International Phase III Study of Vitrase
Dec 04, 2008: ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom 0.09%.
Apr 04, 2003: ISTA Pharmaceuticals Receives FDA Approvable Letter for Vitrase
Jan 04, 2002: ISTA Pharmaceuticals Submits Initial Section of Vitrase NDA
Dec 03, 2004: ISTA Pharmaceuticals Receives FDA Approval for New, Smaller Vial Size for Vitrase
Aug 02, 2004: ISTA Pharmaceuticals Submits Supplemental New Drug Application for Vitrase for Use as a
Spreading Agent
May 01, 2006: ISTA Pharmaceuticals Reports Simple Model Predicts Treatment Success With Vitrase in
Vitreous Hemorrhage Associated With Diabetes
Apr 01, 2008: ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom QD (Once-Daily)
Formulation.
Financial Deals Landscape
ISTA Pharmaceuticals, Inc., Deals Summary
ISTA Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
ISTA Pharmaceuticals Acquires Rights Of Vitrase From Allergan
Partnerships
Ventiv Health Enters Into Co-Promotion Agreement With ISTA Pharmaceuticals
Licensing Agreements
ISTA Pharmaceuticals Amends Licensing Agreement With Senju Pharmaceuticals
ISTA Pharmaceuticals Amends License And Supply Agreement With Otsuka Pharmaceutical
ISTA Pharmaceuticals Enters Into Licensing Agreement With Tanabe Seiyaku
ISTA Pharmaceuticals Enters Into An Licensing Agreement With Senju Pharmaceuticals For Bepotastine
ISTA Pharmaceuticals Enters Into Licensing Agreement With Senju Pharmaceuticals For Latanoprost
ISTA Pharmaceuticals Enters Into Licensing Agreement With Senju Pharmaceuticals For Iganidipine
ISTA Pharmaceuticals Enters Into Licensing Agreement With Senju Pharmaceuticals For Ecabet Sodium
Equity Offering
ISTA Pharmaceuticals Files Registration Statement For Public Offering To Raise Up To $150 Million
ISTA Pharmaceuticals Completes Private Placement Of $37 Million
ISTA Pharmaceuticals Completes Public Offering Of $56 Million
ISTA Pharmaceuticals Completes Private Placement Of $2 Million
ISTA Pharmaceuticals Completes Private Placement Of $13 Million
Debt Offering
ISTA Pharmaceuticals Completes Private Placement Of 8% Senior Notes For $40 Million
Appendix
Methodology
Coverage
Secondary Research
ISTA Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011                                             6
                                                                                Phone: +44 20 8123 2220
                                                                                http://marketpublishers.com


Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

ISTA Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
ISTA Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
ISTA Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
ISTA Pharmaceuticals, Inc. – Phase III, H2 2011
ISTA Pharmaceuticals, Inc. - Phase II, H2 2011
ISTA Pharmaceuticals, Inc. - Phase I, H2 2011
ISTA Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
ISTA Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
ISTA Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
ISTA Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
ISTA Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
ISTA Pharmaceuticals, Inc., Deals Summary, H2 2011
ISTA Pharmaceuticals Acquires Rights Of Vitrase From Allergan
Ventiv Health Enters Into Co-Promotion Agreement With ISTA Pharmaceuticals
ISTA Pharmaceuticals Amends Licensing Agreement With Senju Pharmaceuticals
ISTA Pharmaceuticals Amends License And Supply Agreement With Otsuka Pharmaceutical
ISTA Pharmaceuticals Enters Into Licensing Agreement With Tanabe Seiyaku
ISTA Pharmaceuticals Enters Into An Licensing Agreement With Senju Pharmaceuticals For Bepotastine
ISTA Pharmaceuticals Enters Into Licensing Agreement With Senju Pharmaceuticals For Latanoprost
ISTA Pharmaceuticals Enters Into Licensing Agreement With Senju Pharmaceuticals For Iganidipine
ISTA Pharmaceuticals Enters Into Licensing Agreement With Senju Pharmaceuticals For Ecabet Sodium
ISTA Pharmaceuticals Files Registration Statement For Public Offering To Raise Up To $150 Million
ISTA Pharmaceuticals Completes Private Placement Of $37 Million
ISTA Pharmaceuticals Completes Public Offering Of $56 Million
ISTA Pharmaceuticals Completes Private Placement Of $2 Million
ISTA Pharmaceuticals Completes Private Placement Of $13 Million
ISTA Pharmaceuticals Completes Private Placement Of 8% Senior Notes For $40 Million

LIST OF FIGURES

ISTA Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
ISTA Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
ISTA Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
ISTA Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011
ISTA Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
ISTA Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
ISTA Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011




ISTA Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011                                                7
                                                                                                                              Phone: +44 20 8123 2220
                                                                                                                              http://marketpublishers.com




                                   I would like to order:

                                   Product name:         ISTA Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011
                                   Product link:         http://marketpublishers.com/r/IB4BA146351EN.html
                                   Product ID:           IB4BA146351EN
                                   Price:                US$ 500.00 (Single User License / Electronic Delivery)

                                   If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com


                                   Payment

                                   To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button
                                   on product page http://marketpublishers.com/r/IB4BA146351EN.html




                                   To pay by Wire Transfer, please, fill in your contact details in the form below:

                                   First name:
                                   Last name:
                                   E-mail:
                                   Company:
                                   Address:
                                   City:
                                   Zip/Post Code:
                                   Country:
                                   Tel:
                                   Fax:
                                   Your message:



                                                          * All fields are required



                                   Customer Signature _______________________________________

                                   Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at
                                   http://marketpublishers.com/docs/terms_conditions.html


                                   To place an order via fax simply print this form, fill in the information below
                                   and fax the completed form to +44 20 7900 3970




Powered by TCPDF (www.tcpdf.org)

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:5
posted:3/27/2012
language:English
pages:8